Immune response to Aspergillus fumigatus in compromised hosts: From bedside to bench

Future Microbiology

Volumn 6, Issue 1, 2011, Pages 73-83

  Chai, Louis Ya ^a,b   Vonk, Alieke G ^c   Kullberg, Bart Jan ^a   Netea, Mihai G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cytokine; innate immunity; invasive aspergillosis; macrophage; neutrophil

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; PREDNISOLONE; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ASPERGILLUS FUMIGATUS; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; COMPLEMENT SYSTEM; CYTOKINE RESPONSE; DENDRITIC CELL; DISEASE PREDISPOSITION; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INNATE IMMUNITY; INVASIVE ASPERGILLOSIS; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MACROPHAGE; MONOCYTE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; TH1 CELL; THROMBOCYTE; THROMBOCYTOPENIA;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CYTOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS; PHAGOCYTES; RISK FACTORS;

ASPERGILLUS FUMIGATUS; FUNGI;

EID: 78650504615     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.158     Document Type: Review

References (104)

1. Cornely OA, Maertens J, Winston DJ et al.: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356(4), 348-359 (2007).
2. Neofytos D, Horn D, Anaissie E et al.: Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48(3), 265-273 (2009).
3. Ullmann AJ, Lipton JH, Vesole DH et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356(4), 335-347 (2007).
4. Robenshtok E, Gafter-Gvili A, Goldberg E et al.: Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J. Clin. Oncol. 25(34), 5471-5489 (2007).
5. Caira M, Girmenia C, Fadda RM et al.: Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur. J. Haematol. 81(3), 242-243 (2008).
6. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32(3), 358-366 (2001)
7. Wald A, Leisenring W, van Burik JA, Bowden RA: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 175(6), 1459-1466 (1997).
8. Patterson TF, Kirkpatrick WR, White M et al.: Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79(4), 250-260 (2000).
9. Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100(13), 4358-4366 (2002).
10. Camps IR: Risk factors for invasive fungal infections in haematopoietic stem cell transplantation. Int. J. Antimicrob. Agents 32(Suppl. 2), S119-S123 (2008).
11. Pagano L, Caira M, Candoni A et al.: Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95(4), 644-650 (2010).
12. Fishman JA, Rubin RH: Infection in organ-transplant recipients. N. Engl. J. Med. 338(24), 1741-1751 (1998).
13. Prentice HG, Kibbler CC, Prentice AG: Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br. J. Haematol. 110(2), 273-284 (2000).
14. De Pauw B, Walsh TJ, Donnelly JP et al.: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46(12), 1813-1821 (2008).
15. Schaffner A, Douglas H, Braude A: Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J. Clin. Invest. 69(3), 617-631 (1982).
16. Diamond RD, Clark RA: Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect. Immun. 38(2), 487-495 (1982).
17. Levitz SM, Diamond RD: Mechanisms of resistance of Aspergillus fumigatus conidia to killing by neutrophils in vitro. J. Infect. Dis. 152(1), 33-42 (1985).
18. Segal BH: Aspergillosis. N. Engl. J. Med. 360(18), 1870-1884 (2009).
19. Grimm MJ, Vethanayagam RR, Almyroudis NG et al.: Role of NADPH oxidase in host defense against aspergillosis. Med. Mycol. DOI:10.3109/13693786.2010. 487077 (2010) (Epub ahead of print).
20. Cornish EJ, Hurtgen BJ, McInnerney K et al.: Reduced nicotinamide adenine dinucleotide phosphate oxidase-independent resistance to Aspergillus fumigatus in alveolar macrophages. J. Immunol. 180(10), 6854-6867 (2008).
21. Levitz SM, Farrell TP: Human neutrophil degranulation stimulated by Aspergillus fumigatus. J. Leukoc. Biol. 47(2), 170-175 (1990).
22. Brinkmann V, Reichard U, Goosmann C et al.: Neutrophil extracellular traps kill bacteria. Science 303(5663), 1532-1535 (2004).
23. McCormick A, Heesemann L, Wagener J et al.: NETs formed by human neutrophils inhibit growth of the pathogenic mold Aspergillus fumigatus. Microbes Infect. 12(12-13), 928-936 (2010).
24. Bruns S, Kniemeyer O, Hasenberg M et al.: Production of extracellular traps against Aspergillus fumigatus in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin RodA. PLoS Pathog. 6(4), e1000873 (2010).
25. Bianchi M, Hakkim A, Brinkmann V et al.: Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 114(13), 2619-2622 (2009).
26. Bonnett CR, Cornish EJ, Harmsen AG, Burritt JB: Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus conidia. Infect. Immun. 74(12), 6528-6539 (2006).
27. Mircescu MM, Lipuma L, van Rooijen N, Pamer EG, Hohl TM: Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection. J. Infect. Dis. 200(4), 647-656 (2009).
28. Svirshchevskaya EV, Shevchenko MA, Huet D et al.: Susceptibility of mice to invasive aspergillosis correlates with delayed cell influx into the lungs. Int. J. Immunogenet. 36(5), 289-299 (2009).
29. Ibrahim-Granet O, Philippe B, Boleti H et al.: Phagocytosis and intracellular fate of Aspergillus fumigatus conidia in alveolar macrophages. Infect. Immun. 71(2), 891-903 (2003). (Pubitemid 36150785)
30. Behnsen J, Narang P, Hasenberg M et al.: Environmental dimensionality controls the interaction of phagocytes with the pathogenic fungi Aspergillus fumigatus and Candida albicans. PLoS Pathog. 3(2), e13 (2007).
31. Romani L: Immunity to fungal infections. Nat. Rev. Immunol. 4(1), 1-23 (2004).
32. Netea MG, Brown GD, Kullberg BJ, Gow NA: An integrated model of the recognition of Candida albicans by the innate immune system. Nat. Rev. Microbiol. 6(1), 67-78 (2008).
33. Park SJ, Mehrad B: Innate immunity to Aspergillus species. Clin. Microbiol. Rev. 22(4), 535-551 (2009).
34. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM: Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J. Biol. Chem. 277(42), 39320-39326 (2002).
35. Wang JE, Warris A, Ellingsen EA et al.: Involvement of CD14 and Toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect. Immun. 69(4), 2402-2406 (2001).
36. Bellocchio S, Montagnoli C, Bozza S et al.: The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J. Immunol. 172(5), 3059-3069 (2004).
37. Steele C, Rapaka RR, Metz A et al.: The b-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus. PLoS Pathog. 1(4), e42 (2005).
38. Bochud PY, Chien JW, Marr KA et al.: Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N. Engl. J. Med. 359(17), 1766-1777 (2008).
39. Cunha C, Di Ianni M, Bozza S et al.: Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood (2010) (Epub ahead of print).
40. Chai LY, de Boer MG, van der Velden WJ et al.: The Y238X stop codon polymorphism in the human b-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J. Infect. Dis. (2011) (In press).
41. Aimanianda V, Bayry J, Bozza S et al.: Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 460(7259), 1117-1121 (2009).
42. Elenkov IJ: Glucocorticoids and the Th1/Th2 balance. Ann. NY Acad. Sci. 1024, 138-146 (2004).
43. Ng TT, Robson GD, Denning DW: Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140(Pt 9), 2475-2479 (1994).
44. Barnes PJ: Mechanisms and resistance in glucocorticoid control of inflammation. J. Steroid Biochem. Mol. Biol. 120(2-3), 76-85 (2010).
45. Ibrahim-Granet O, Jouvion G, Hohl TM et al.: In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis. BMC Microbiol. 10, 105 (2010).
46. Chignard M, Balloy V, Sallenave JM, Si-Tahar M: Role of Toll-like receptors in lung innate defense against invasive aspergillosis. Distinct impact in immunocompetent and immunocompromized hosts. Clin. Immunol. 124(3), 238-243 (2007).
47. Diamond RD: Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones. J. Infect. Dis. 147(1), 160 (1983).
48. Chai LY, Kullberg BJ, Vonk AG et al.: Modulation of Toll-like receptor 2 (TLR2) and TLR4 responses by Aspergillus fumigatus. Infect. Immun. 77(5), 2184-2192 (2009).
49. Simitsopoulou M, Roilides E, Paliogianni F et al.: Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob. Agents Chemother. 52(9), 3301-3306 (2008).
50. Serbina NV, Cherny M, Shi C et al.: Distinct responses of human monocyte subsets to Aspergillus fumigatus conidia. J. Immunol. 183(4), 2678-2687 (2009).
51. Hohl TM, Rivera A, Lipuma L et al.: Inflammatory monocytes facilitate adaptive CD4 T cell responses during respiratory fungal infection. Cell Host Microbe 6(5), 470-481 (2009).
52. Christin L, Wysong DR, Meshulam T, Hastey R, Simons ER, Diamond RD: Human platelets damage Aspergillus fumigatus hyphae and may supplement killing by neutrophils. Infect. Immun. 66(3), 1181-1189 (1998).
53. Perkhofer S, Kehrel BE, Dierich MP et al.: Human platelets attenuate Aspergillus species via granule-dependent mechanisms. J. Infect. Dis. 198(8), 1243-1246 (2008).
54. Rodland EK, Ueland T, Pedersen TM et al.: Activation of platelets by Aspergillus fumigatus and potential role of platelets in the immunopathogenesis of Aspergillosis. Infect. Immun. 78(3), 1269-1275 (2010).
55. Netea MG, Van der Meer JW, Sutmuller RP, Adema GJ, Kullberg BJ: From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob. Agents Chemother. 49(10), 3991-3996 (2005).
56. Stevens DA: Th1/Th2 in aspergillosis. Med. Mycol. 44(6 Suppl. 1), 229-235 (2006).
57. Hebart H, Bollinger C, Fisch P et al.: Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 100(13), 4521-4528 (2002).
58. Chai LY, Netea MG, Teerenstra S et al.: Early proinflammatory cytokines and C-reactive protein tends as predictors of outcome in invasive aspergillosis. J. Infect. Dis. 202(9), 1454-1462 (2010).
59. Rivera A, Van Epps HL, Hohl TM, Rizzuto G, Pamer EG: Distinct CD4+-T-cell responses to live and heat-inactivated Aspergillus fumigatus conidia. Infect. Immun. 73(11), 7170-7179 (2005).
60. Safdar A: Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist 12(Suppl. 2), 2-6 (2007).
61. Shao C, Qu J, He L et al.: Transient overexpression of g interferon promotes Aspergillus clearance in invasive pulmonary aspergillosis. Clin. Exp. Immunol. 142(2), 233-241 (2005).
62. Marty FM, Lee SJ, Fahey MM et al.: Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102(8), 2768-2776 (2003).
63. Mehrad B, Strieter RM, Standiford TJ: Role of TNF-a in pulmonary host defense in murine invasive aspergillosis. J. Immunol. 162(3), 1633-1640 (1999). (Pubitemid 29307039)
64. Duong M, Ouellet N, Simard M, Bergeron Y, Olivier M, Bergeron MG: Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J. Infect. Dis. 178(5), 1472-1482 (1998).
65. Cenci E, Mencacci A, Casagrande A, Mosci P, Bistoni F, Romani L: Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. J. Infect. Dis. 184(5), 610-617 (2001).
66. Montagnoli C, Fallarino F, Gaziano R et al.: Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J. Immunol. 176(3), 1712-1723 (2006).
67. Roilides E, Sein T, Roden M, Schaufele RL, Walsh TJ: Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis. J. Infect. Dis. 183(3), 518-520 (2001).
68. Kolls JK, Linden A: Interleukin-17 family members and inflammation. Immunity 21(4), 467-476 (2004).
69. Peck A, Mellins ED: Precarious balance: Th17 cells in host defense. Infect. Immun. 78(1), 32-38).
70. Huang W, Na L, Fidel PL, Schwarzenberger P: Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J. Infect. Dis. 190(3), 624-631 (2004).
71. Zelante T, Bozza S, De Luca A et al.: Th17 cells in the setting of Aspergillus infection and pathology. Med. Mycol. 47(Suppl. 1), S162-S169 (2009).
72. Werner JL, Metz AE, Horn D et al.: Requisite role for the dectin-1 b-glucan receptor in pulmonary defense against Aspergillus fumigatus. J. Immunol. 182(8), 4938-4946 (2009).
73. Chai LY, van de Veerdonk F, Marijnissen RJ et al.: Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology 130(1), 46-54 (2010).
74. Garlanda C, Hirsch E, Bozza S et al.: Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420(6912), 182-186 (2002).
75. D'Angelo C, De Luca A, Zelante T et al.: Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J. Immunol. 183(7), 4609-4618 (2009).
76. Kozel TR, Wilson MA, Farrell TP, Levitz SM: Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae. Infect. Immun. 57(11), 3412-3417 (1989).
77. Dumestre-Perard C, Lamy B, Aldebert D et al.: Aspergillus conidia activate the complement by the mannan-binding lectin C2 bypass mechanism. J. Immunol. 181(10), 7100-7105 (2008).
78. Kaur S, Gupta VK, Thiel S, Sarma PU, Madan T: Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. Clin. Exp. Immunol. 148(2), 382-389 (2007).
79. Serrano-Gomez D, Dominguez-Soto A, Ancochea J, Jimenez-Heffernan JA, Leal JA, Corbi AL: Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin mediates binding and internalization of Aspergillus fumigatus conidia by dendritic cells and macrophages. J. Immunol. 173(9), 5635-5643 (2004).
80. Serrano-Gomez D, Leal JA, Corbi AL: DC-SIGN mediates the binding of Aspergillus fumigatus and keratinophylic fungi by human dendritic cells. Immunobiology 210(2-4), 175-183 (2005).
81. Bozza S, Gaziano R, Spreca A et al.: Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J. Immunol. 168(3), 1362-1371 (2002).
82. Rivera A, Ro G, Van Epps HL et al.: Innate immune activation and CD4+ T cell priming during respiratory fungal infection. Immunity 25(4), 665-675 (2006).
83. Del Sero G, Mencacci A, Cenci E et al.: Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect. 1(14), 1169-1180 (1999).
84. Rivera A, Collins N, Stephan MT, Lipuma L, Leiner I, Pamer EG: Aberrant tissue localization of fungus-specific CD4+ T cells in IL-10-deficient mice. J. Immunol. 183(1), 631-641 (2009).
85. Ferrara JL, Levine JE, Reddy P, Holler E: Graft-versus-host disease. Lancet 373(9674), 1550-1561 (2009).
86. Socie G, Blazar BR: Acute graft-versus-host disease: from the bench to the bedside. Blood 114(20), 4327-4336 (2009).
87. Mezger M, Wozniok I, Blockhaus C et al.: Impact of mycophenolic acid on the functionality of human polymorphonuclear neutrophils and dendritic cells during interaction with Aspergillus fumigatus. Antimicrob. Agents Chemother. 52(7), 2644-2646 (2008).
88. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR: Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin. Infect. Dis. 43(1), 16-24 (2006).
89. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and g interferon. Infect. Immun. 61(4), 1185-1193 (1993). (Pubitemid 23099183)
90. Sionov E, Mendlovic S, Segal E: Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J. Antimicrob. Chemother. 56(3), 594-597 (2005).
91. Roilides E, Holmes A, Blake C, Venzon D, Pizzo PA, Walsh TJ: Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-g. J. Infect. Dis. 170(4), 894-899 (1994).
92. Brummer E, Kamberi M, Stevens DA: Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J. Infect. Dis. 187(4), 705-709 (2003).
93. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J. Clin. Oncol. 23(18), 4198-4214 (2005).
94. Smith TJ, Khatcheressian J, Lyman GH et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24(19), 3187-3205 (2006).
95. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S: Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin. Infect. Dis. 17(4), 705-707 (1993).
96. Bandera A, Trabattoni D, Ferrario G et al.: Interferon-g and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis. Infection 36(4), 368-373 (2008).
97. Choi JH, Brummer E, Kang YJ, Jones PP, Stevens DA: Inhibitor kB and nuclear factor kB in granulocyte-macrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia. J. Infect. Dis. 193(7), 1023-1028 (2006).
98. Kelleher P, Goodsall A, Mulgirigama A et al.: Interferon-g therapy in two patients with progressive chronic pulmonary aspergillosis. Eur. Respir. J. 27(6), 1307-1310 (2006).
99. Safdar A, Rodriguez G, Ohmagari N et al.: The safety of interferon-g-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 103(4), 731-739 (2005).
100. Beck O, Topp MS, Koehl U et al.: Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 107(6), 2562-2569 (2006).
101. Tramsen L, Koehl U, Tonn T et al.: Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant. 43(1), 13-19 (2009).
102. Perruccio K, Tosti A, Burchielli E et al.: Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106(13), 4397-4406 (2005).
103. Bozza S, Perruccio K, Montagnoli C et al.: A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 102(10), 3807-3814 (2003).
104. Bozza S, Clavaud C, Giovannini G et al.: Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J. Immunol. 183(4), 2407-2414 (2009).